A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).

被引：0
|
作者：
Guo, Changying
Chen, Shengjia
Ye, Yongqiang
Mao, Wei-Min
机构：
[1] Jiangxi Prov Tumor Hosp, Nanchang, Jiangxi, Peoples R China
[2] Jiujiang 1 Peoples Hosp, Jiujiang, Peoples R China
[3] Ganzhou Canc Hosp, Ganzhou, Peoples R China
[4] Zhejing Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS488
引用
收藏
页码：TPS488 / TPS488
页数：1
相关论文
共 50 条
  • [1] Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).
    Guo, Changying
    Chen, Shengjia
    Ye, Yongqiang
    Li, Xiao-Bing
    Mao, Weimin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 347 - 347
  • [2] Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005).
    Guo, Changying
    Li, Xiaobing
    Chen, Shengjia
    Ye, Yongqiang
    Mao, Weimin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [3] ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Zheng, Jinfang
    Fu, Changbo
    Xu, Guohui
    Bai, Yannan
    Wu, Changxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS632 - TPS632
  • [4] Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
    Mao, X.
    Duan, X.
    Wu, D.
    Zhou, C.
    Tian, Y.
    Shen, J.
    Xu, G.
    Bai, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S658 - S658
  • [5] Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Shen, Jian
    Xu, Guohui
    Lai, Jianlin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 494 - 494
  • [6] A phase Ib study of anlotinib plus TQB2450 as a second-line investigational therapy in advanced hepatocellular carcinoma (aHCC).
    Zhang, Wen
    Sun, Yongkun
    Zeng, Huiying
    Zhu, Zheng
    Liang, Meng
    Han, Yue
    Yan, Dong
    Chen, Bo
    Huang, Zhen
    Bi, Xinyu
    Zhao, Hong
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16184 - E16184
  • [7] A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
    Wang, Jiayu
    Sun, Tao
    Ouyang, Quchang
    Han, Yiqun
    Xu, Binghe
    ISCIENCE, 2023, 26 (06)
  • [8] First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.
    Wang, Jiayu
    Xu, Binghe
    Sun, Tao
    Ouyang, Quchang
    Han, Yiqun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Luo, Yang
    Fan, Ying
    Cai, Ruigang
    Li, Qiao
    Lan, Bo
    Mo, Hongnan
    Wang, Jiani
    Li, Yiqun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A phase Ib study of anlotinib plus TQB2450 as second-line therapy for advanced biliary tract adenocarcinoma.
    Sun, Yongkun
    Zhou, Aiping
    Zhang, Wen
    Jiang, Zhichao
    Qu, Wang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345